Funded Tech Companies
Brainstorm Cell Therapeutics
Wondering who provided funding to Brainstorm Cell Therapeutics? Private investors put venture money into this biopharmaceutical company.
Company Overview
Company Name
Brainstorm Cell Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
1325 Avenue of Americas, 28th Floor
New York City, NY 10019
US
New York City, NY 10019
US
Phone
Website
Email Address
Company Background Information
Overview
BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson's disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm's proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Inst
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
2/20/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chaim Lebovits
Chief Operating Officer
Haro Hartounian
Company Investors
Browse more funded tech companies:
BrainStorm | Brainstorm Health Services
Share this article
About Our VC Funding Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs